Podcast: Key Business Considerations for Growing BioPharm Product Pipeline
Feb 10, 2012
By BioPharm International Editors
In this first intervew with BioPharm International, Tarja Mottram, CEO of Action for Results, discusses some of the deeper business considerations for companies planning to grow with a pipeline or portfolio. Posted Feb. 2012.
FDA set several milestones in approving more new, important drugs and biologics in 2014. Breakthrough drug designations went through through the roof, speeding more new therapies for cancer and critical conditions to patients.